Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Type 2 Diabetes Mellitus: early-phase trial registry
15 of 131 indexed Type 2 Diabetes Mellitus trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #91 of 28,707 conditions by registered trial count.
131 US clinical trials · 15 currently recruiting · #91 of 28,707 conditions by registered trial count
Type 2 Diabetes Mellitus: 131 US clinical trials tracked, 15 recruiting.
Type 2 Diabetes Mellitus is the subject of 131 registered US clinical trials on ClinicalTrials.gov, 15 of them currently open to new participants. 26 are in Phase 3-4 (later-stage) and 52 in Phase 1-2 (earlier-stage). The most active sponsor is AstraZeneca, running 11 of these trials.
Enrollment posture brief
Registry condition type-2-diabetes-mellitus
OPEN 15 | RECR 11% | LATE 26 | EARLY 52 | RANK #91 | SPON 11
Volume-matched condition peers
Nearest open-share peer: Actinic Keratosis (12% recruiting · 17 trials)
Type 2 Diabetes Mellitus lists 15 open slots (11% of 131 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Type 2 Diabetes Mellitus on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Type 2 Diabetes Mellitus is recruiting below its size-band peers.
15 of 131 indexed trials (11.5%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Type 2 Diabetes Mellitus trials is spread across many organizations.
AstraZeneca accounts for 11 of 131 trials (8.4%). 82 distinct sponsors appear on at least one study for this condition label.
-
Typical Type 2 Diabetes Mellitus enrolment sits around 70 participants.
Median target enrolment is 70 among the 131 trials that report a genuine target (sentinel values excluded). 76 of those (58%) plan for fewer than 100 participants.
-
Type 2 Diabetes Mellitus research is mostly interventional.
116 interventional and 15 observational studies make up this index (88.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
131 total, page 2 of 3
To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies
Novartis
NCT01068860
Colesevelam for Children With Type 2 Diabetes
Daiichi Sankyo
NCT01258075
An Open-label, Multi-center, International, Three-year, Safety and Tolerability 'Follow on' Trial
Mannkind Corporation
NCT00754624
REAL HEALTH-Diabetes: Reach Ahead for Lifestyle and Health-Diabetes
Massachusetts General Hospital
NCT02320253
A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin
Pfizer
NCT02554877
A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes
vTv Therapeutics
NCT01665352
The Efficacy and Treatment Adherence With an Integrated Program on HbA1c Scores in Patients With Type 2 Diabetes
KRJG Services
NCT01626053
Integrating Depression Services Into DM Management
University of Pennsylvania
NCT01098253
University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial)
University of Florida
NCT00994682
Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)
Merck Sharp & Dohme
NCT04029480
Ginkgo Biloba Extract and the Insulin Resistance Syndrome
National Center for Complementary and Integrative Health (NCCIH)
NCT00032474
A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus
Ligand Pharmaceuticals
NCT02851849
Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00212290
Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
Response Pharmaceuticals
NCT02434744
Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes
Massachusetts General Hospital
NCT03818581
Physical Activity and Participation
VA Office of Research and Development
NCT02268916
Long Term Free Living Study With Modified Foods and Type 2 Diabetics
Johns Hopkins Bloomberg School of Public Health
NCT00198913
Mil Familias-Santa Barbara's Operational Pilot to Understand Diabetes in the Latino Community
Sansum Diabetes Research Institute
NCT03736486
4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes
Pfizer
NCT03538743
Exercise Training and Glucose Metabolism in Aging
US Department of Veterans Affairs
NCT00701051
Safety and Efficacy Study of PN2034 in Type 2 Diabetes Patients on Concomitant Rosiglitazone and Metformin (or Avandamet)
Wellstat Therapeutics
NCT00110851
Surgery or Lifestyle With Intensive Medical Management in the Treatment of Type 2 Diabetes
Joslin Diabetes Center
NCT01073020
A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12460A
Hanmi Pharmaceutical Company Limited
NCT01724814
A Phase 1 Single/Multiple Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus
Pfizer
NCT02211261
A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease
Prokidney
NCT02836574
Dance Dance Revolution (DDR) in Type 2 Diabetes
Charles Drew University of Medicine and Science
NCT00851019
Adding Liraglutide to High Dose Insulin: Breaking the Cycle
Ildiko Lingvay
NCT01505673
A Trial to Assess Steviol Glycosides on Acute Appetite Hormone Release
Midwest Center for Metabolic and Cardiovascular Research
NCT05287906
A Bioequivalence Study Testing Two Formulations of Sotagliflozin in Healthy Male and Female Subjects Under Fasted Conditions
Sanofi
NCT03776227
A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly Suspension
AstraZeneca
NCT00894322
Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus
Brigham and Women's Hospital
NCT00762671
Financial Incentives Telephone Education and Skills Trial in African Americans With Diabetes (FITEST)
State University of New York at Buffalo
NCT02722499
Effect of Diabetes Mellitus on Cholesterol Metabolism
Medical College of Wisconsin
NCT00879710
Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome
Baylor Research Institute
NCT02251431
Grocery Prescription Program for Medicaid Adults With Hypertension or Type 2 Diabetes
Alison Gustafson
NCT06033664
TAK-648 Multiple-Rising Dose Study in Healthy Japanese Participants and Non-Japanese Participants With Type 2 Diabetes Mellitus
Takeda
NCT02430870
Yo Puedo! Diabetes Self-Management Education + mHealth in Mexico City
Yale University
NCT03159299
Diabetes Prevention and Control in the Workplace: A Pilot Study
State University of New York - Upstate Medical University
NCT00739336
Ketones, Muscle Metabolism, and SGLT2 Inhibitors - Protocol 1
The University of Texas Health Science Center at San Antonio
NCT03560323
Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients
St. Paul Heart Clinic
NCT00123643
A Study to Compare the Safety and Drug Levels in Blood When Using Various Forms of GSK189075 Given to Healthy Subjects
GlaxoSmithKline
NCT00559884
Effects on Colesevelam HC1 (WelChol®) on Insulin Sensitivity in Subjects With Type 2 Diabetes Mellitus
Daiichi Sankyo
NCT00361153
Study to Assess Safety and Pharmacokinetics of Double-Blind S-707106 Alone and in Combination With Open-Label Metformin in Patients With Type 2 Diabetes Mellitus
Shionogi
NCT01154348
Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes
Pacira Pharmaceuticals
NCT02762370
Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes
Rocky Mountain Diabetes and Osteoporosis Center
NCT01341067
Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes
AstraZeneca
NCT00241423
A Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX in Subjects With Type 2 Diabetes Mellitus (T2DM)
AstraZeneca
NCT02367066
Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects
AstraZeneca
NCT00904176
A Comparison Of Study Drug Blood Levels After One Dose Of GSK189075 In Subjects With Normal And Reduced Kidney Function
GlaxoSmithKline
NCT00501462
Antioxidant Effects of Pomegranate Juice Versus Placebo in Adults With Type 2 Diabetes Mellitus
University of Colorado, Denver
NCT00668954
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 29 |
| Phase 2 | 23 |
| Phase 3 | 16 |
| Phase 4 | 10 |
Top Sponsors
Named interventions
Most-linked intervention names on Type 2 Diabetes Mellitus records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Type 2 Diabetes Mellitus trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Type 2 Diabetes Mellitus page
131 registered trials, 15 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 15 Type 2 Diabetes Mellitus trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- AstraZeneca sponsors the most Type 2 Diabetes Mellitus trials on record, review their full trial history before evaluating a specific study. See AstraZeneca's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Type 2 Diabetes Mellitus condition card totals 131 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.